References
- Emerson SG. Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: the next generation of cellular therapeutics. Blood 1996; 87: 3082–8
- Haylock DN, Makino S, Dowse TL, et al. Ex vivo hematopoietic progenitor cell expansion. Immunomethods 1994; 5: 217–25
- Haylock DN, To LB, Dowse TL, et al. Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood 1992; 80: 1405–12
- Brugger W, Heimfeld S, Berenson RJ, et al. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 1995; 3: 283–7
- Williams SF, Lee WJ, Bender JG, et al. Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer. Blood 1996; 87: 1687–91
- Gluckman E. Current status of umbilical cord blood hematopoietic stem cell transplantation. Exp Hematol 2000; 28: 1197–205
- McNiece I, Kubegov D, Kerzic P, et al. Increased expansion and differentiation of cord blood products using a two-step expansion culture. Exp Hematol 2000; 28: 1181–6
- Cassel A, Cottler-Fox M, Doren S, Dunbar CE. Retroviral-mediated gene transfer into CD34 enriched human peripheral blood stem cells. Exp Hematol 1993; 21: 585–91
- Nolta JA, Smogorzewska EM, Kohn DB. Analysis of optimal conditions for retroviral-mediated transduction of primitive human hematopoietic cells. Blood 1995; 86: 101–10
- Amado RG, Mitsuyasu RT, Rosenblatt JD, et al. Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther 2004; 15: 251–62
- Prince HM, Simmons PJ, Whitty G, et al. Improved hemopoietic recovery following transplantation with ex vivo expanded mobilized blood cells. Brit J Haematol 2004; 126: 536–45
- Reiffers J, Cailliot C, Dazey B, et al. Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells. Lancet 1999; 354: 1092–3
- Paquette RL, Karpf E, Wang H-J, et al. Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. Blood 2000; 96: 2385–90
- McNiece I, Jones R, Bearman SI, et al. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. Blood 2000; 96: 3001–7
- Prince HM, Rischin D, Toner GC, et al. Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study. Bone Marrow Transplant 2000; 26: 955–61
- Prince HM, Bashford J, Wall D, et al. Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy. Cytotherapy 2002; 4: 137–45
- Reichle A, Zaiss M, Rothe G, et al. Autologous tandem transplantation: almost complete reduction of neutropenic fever following the second transplantation by ex vivo expanded autologous myeloid post progenitor cells. Bone Marrow Transplant 2003; 32: 299–305